The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.
The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.
In separate deals announced this past week, the German biotech firm will distribute assays developed by Asuragen, and co-develop, co-manufacture, and co-market assays with Mikrogen.
The company is collaborating with fellow German biotech firm Mikrogen to identify autoantibody signatures typical of various infectious diseases.
The German firms said this week that they have conducted a feasibility study for identifying autoantibody signatures in infectious diseases that may be useful for future diagnostics.
The firms are working on infectious disease diagnostics using Protagen's UNIarray platform.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.